entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 18:17:44 - browse：781

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： New Alzheimer's drugs heat up race for early detection blood tests

WSS

What to watch for from Zogenix and Amicus clinical trials

Biden warns of ‘dark winter’ during final presidental debate

GOP inquiry over gain

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Tuskegee Airman Raymond Cassagnol dies at 102

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

entertainment

entertainment

knowledge

Sports medicine is finally prioritizing gender equality

ADA: All diabetes patients should be screened for liver condition

Peter Hotez and the public health issue of online harassment

CDC Director Mandy Cohen on transparency, trust, and health

Hollywood unions extend contract negotiations for actors

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Apple is now the first public company to be valued at $3 trillion

STAT Report: Patient voices and perspectives

Trump demands the U.S. pay no more for drugs than other countries … again

Medical experts exlpore how to eliminate bias in clinical algorithms

entertainment

Dems pitch expanding Medicare power to negotiate drug prices

A new crop of companies is reshaping the health data economy

Truvian presents data for its desktop blood

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Rise in cancer among younger people worries and puzzles doctors

The simple reason for the increase in autism diagnosis

leisure time

Wikipedia

focus

hotspot